信达生物(01801.HK)双特异性抗体产品完成国外首例患者给药
信达生物(01801.HK)公布,旗下其潜在首创抗CD47/PD-L1双特异性抗体产品(IBI322),於第一期临床研究已完成国外首例患者给药。
该项研究於美国开展,为评估IBI322治疗晚期恶性肿瘤受试者的Ia期临床研究,研究主要目的为评估IBI322双特异性抗体治疗在标准治疗失败的晚期恶性肿瘤受试者中的安全性、耐受性和抗肿瘤活性。
信达生物制药集团医学科学与战略肿瘤部副总裁周辉表示,双特异性抗体将效应细胞直接靶向肿瘤细胞,可以增强细胞毒性,比单特异性抗CD47抗体具有更良好的体内功效、肿瘤富集分布以及更高的安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.